[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

646-902-9271

Email address

loeserb@samustherapeutics.com

Condition

Alzheimer Disease

Treatment type

Interventional

Investigational product

Rating Scales

Phase

Phase 2

Sponsor

Samus Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT04311515

Study number

PU-AD-SD-0201

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects of oral PU AD (dihydrochloride salt) in subjects with mild AD

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. inclusive) 2. Diagnosis of probable AD dementia based on National Institute on Aging and Alzheimer's Association (NIA/
  2. AA) AD Dementia diagnostic criteria 3. Mild AD as assessed by Mini Mental State Examination (
  3. MMSE) score between 18 to 26 at Screening Visit (
  4. inclusive) 4. Tau positive as evaluated by Tau PET using 18F-PI-2620 and assessment of tracer uptake in the medial temporal lobe and any cortical regions associated with Alzheimer's disease. 5. Geriatric Depression Scale score of ≤ 6 (on the staff administered short
  5. form) 6. Magnetic resonance imaging (
  6. MRI) or computerized tomography (
  7. CT) scan performed within the past 2 years that has confirmed no findings inconsistent with a diagnosis of AD 7. Subjects or his/her caregiver and/or legally authorized representative must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (
  8. IEC) approved written Informed Consent Form (
  9. ICF) 8. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study 9. Must have one caregiver who, in the investigator's judgment, has frequent and sufficient contact with the subject (at least 10 hours/
  10. week) and is able to provide accurate information about the subject's cognitive and functional abilities; the caregiver must agree to, accompany the subject to clinic visits and/or be available by phone at designated times to provide information to the investigator and study staff about the subject, attend in person clinic visits that require partner input for scale completion, and must agree to monitor the subject's administration of any prescribed medications 10. Female must either be post menopausal (no menstrual period for >1 year), or surgically sterilized (by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). 11. Males who are sexually active and whose partners are females of childbearing potential must agree to use condoms from screening through 90 days after administration of the last dose of IMP; their partners must be willing to use a medically acceptable method of contraception (a barrier method, intrauterine device, or hormonal
  11. contraception) from screening through 90 days after administration of the last dose of IMP 12. Must consent to Apolipoprotein E (
  12. ApoE) genotyping; the subject's ApoE status may be disclosed to him/her at the investigator's discretion -
Exclusion criteria
  1. AIREN) criteria for vascular dementia 2. Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and pharmacologic effect in this study; or has a life expectancy of < 2 years 3. Has had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness 4. Has a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate specific antigen post treatment 5. Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post treatment hypersensitivity reactions 6. Has a "yes" answer to Columbia Suicide Severity Rating Scale (C-
  2. SSRS) suicidal ideation item 4 or 5, or any suicidal behavior assessment within 6 months of Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening 7. Has received acetylcholinesterase inhibitor (AChEIs), memantine, and/or other AD therapy for less than 4 months or has less than 2 months of stable therapy on these treatments 8. Has not been stable on medications that affect the Central nervous system (CNS), for at least 4 weeks (including antidepressants, hypnotics, antipsychotics, etc.) except occasional use of benzodiazepine (definition of occasional use - not more than twice in a week or three times in a month during the past 3 months). 9. Has a history of chronic alcohol or drug abuse/dependence within the past 5 years 10. Any medical or neurological/neurodegenerative condition (other than
  3. AD) that, in the opinion of the investigator, might be a contributing cause to the subject's cognitive impairment (e.g., current history of substance abuse, uncontrolled vitamin B12 deficiency or abnormal thyroid function, stroke or other cerebrovascular condition, Parkinson's disease, Lewy body dementia, or frontotemporal
  4. dementia) 11. Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening Visit 12. History of bleeding disorder or predisposing conditions, blood clotting, or clinically significant abnormal results on coagulation profile at Screening, as determined by the investigator 13. History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class III or IV), or clinically significant conduction abnormalities (e.g., unstable atrial
  5. fibrillation) within 1 year prior to Screening Visit 14. Clinically significant 12 lead Electrocardiogram (
  6. ECG) abnormalities, as determined by the investigator 15. Indication of impaired liver function as shown by an abnormal liver function profile at Screening (e.g., repeated values of Aspartate aminotransferase (
  7. AST) and Alanine aminotransferase (
  8. ALT) ≥ 2 × the upper limit of normal [ULN]) and/or indication of impaired renal function at Screening (e.g., repeated values of creatinine and blood urea nitrogen [BUN] ≥ 1.5 × Upper limit of normal (
  9. ULN) or estimated glomerular filtration rate < 45 mL/minute/1.73 m2 and corroborating medical history and physical
  10. examination) 16. Contraindications to having a brain Magnetic resonance imaging (
  11. MRI) (e.g., MRI incompatible pacemaker; MRI incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed); if the MRI compatibility of implanted devices is unknown, the subject must be excluded from the study 17. Contraindication to having a PET brain scan (e.g., inability to lie flat or still for the duration of the
  12. scan) or intolerance to previous PET scans (i.e., previous hypersensitivity reactions to any PET ligand or imaging agent, failure to participate in and comply with previous PET
  13. scans) 18. Contraindication to having an FDG PET scan, including uncontrollable glucose levels, inability to fast for the prescribed number of hours prior to the FDG PET scan, inability to withhold all insulin and oral diabetic medication after midnight prior to the PET scan 19. Inability to refrain from using sleep medication for the 24 hours prior to each FDG PET scan or to refrain from use of antipsychotics, sedatives, or other strong acting neuropsychiatric medication on the day of each PET scan prior to the scan 20. Current or recent participation (within 12 months before
  14. screening) in any procedures involving radioactive agents such that radiation exposure of the, in the judgement of the investigator (upon review of medical history), subject in any given year would exceed the whole-body limits of annual and total dose commitment of 5 rems set forth in the US Code of Federal Regulations (
  15. CFR) Title 21 section 361.1. 21. Any contraindications to lumbar puncture (LP), e.g., increased bleeding risk (platelet count <100,000/μL, coagulopathies, anticoagulant drugs), lumbar spine deformity that might interfere with the procedure evidence on MRI contraindicating LP, risk for cerebral herniation, space occupying lesion with mass effect, abnormal intracranial pressure due to increased CSF pressure, Arnold Chiari malformation, local infections at the puncture site and patient fear of LP; abnormalities in the screening CSF profile that are considered by the Investigator to be clinically significant are exclusionary 22. Any major surgery within 12 weeks of Screening Visit or during the Screening Period 23. Has active ocular condition that in the opinion of the investigator may alter visual acuity during the course of the study. 24. Use of any drugs that are strong inhibitors of Cytochrome (CYP)450 (2D6 or
  16. 2C19) within 7 days or 5 half lives of the inhibitor (whichever is longer), prior to administration of the first dose of Investigational medicinal product (
  17. IMP) and/or plan to use throughout the study 25. Participation within the 12 months prior to Screening Visit in a study of any agent(
  18. s) with a purported disease modifying effect in AD (e.g., anti beta amyloid, β secretase inhibitors, γ secretase inhibitors), unless documentation of receipt of placebo is available 26. Has taken other investigational drugs or participated in any clinical study within 30 days or 5 half lives (if
  19. known) of the investigational drug, whichever is longer, prior to first dose of IMP in this study or is currently participating in another clinical study 27. Other unspecified reasons that, in the opinion of the investigator or Samus, and/or its delegated medical monitor, make the subject unsuitable for the study -

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site